MCID: GST040
MIFTS: 63

Gastric Adenocarcinoma

Categories: Cancer diseases, Gastrointestinal diseases

Aliases & Classifications for Gastric Adenocarcinoma

MalaCards integrated aliases for Gastric Adenocarcinoma:

Name: Gastric Adenocarcinoma 12 15 73
Adenocarcinoma of Stomach 12 6
Stomach Adenocarcinoma 12
Adenocarcinoma Gastric 55

Classifications:



External Ids:

Disease Ontology 12 DOID:3717
NCIt 50 C4004
SNOMED-CT 68 408647009
UMLS 73 C0278701

Summaries for Gastric Adenocarcinoma

Disease Ontology : 12 A stomach carcinoma that derives from epithelial cells of glandular origin.

MalaCards based summary : Gastric Adenocarcinoma, also known as adenocarcinoma of stomach, is related to gastric papillary adenocarcinoma and adenocarcinoma, and has symptoms including dyspepsia An important gene associated with Gastric Adenocarcinoma is SMAD4 (SMAD Family Member 4), and among its related pathways/superpathways are Innate Immune System and Apoptotic Pathways in Synovial Fibroblasts. The drugs Taxotere and Fluorouracil have been mentioned in the context of this disorder. Affiliated tissues include lymph node, liver and bone, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 76 Stomach cancer, also known as gastric cancer, is cancer developing from the lining of the stomach. Early... more...

Related Diseases for Gastric Adenocarcinoma

Diseases related to Gastric Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 251)
# Related Disease Score Top Affiliating Genes
1 gastric papillary adenocarcinoma 33.5 ERBB2 TP53
2 adenocarcinoma 32.4 BRAF ERBB2 FGFR1 FGFR2 H19 HRAS
3 peutz-jeghers syndrome 31.6 PTEN SMAD4 TP53
4 gastrointestinal stromal tumor 31.4 BRAF HOTAIR PTEN TP53
5 lipomatosis 31.1 FGFR1 PIK3CA PTEN
6 cowden disease 31.0 PIK3CA PTEN SMAD4
7 testicular germ cell tumor 30.8 BRAF PTEN TP53
8 colorectal adenocarcinoma 30.7 BRAF HRAS TP53
9 leukemia 30.2 HOTAIR NEAT1 NRAS RAF1 TP53
10 squamous cell carcinoma 30.2 BRAF ERBB2 FGFR2 H19 HOTAIR HRAS
11 myeloma, multiple 30.1 BRAF H19 HOTAIR HRAS NRAS TP53
12 glioma 29.9 BRAF ERBB2 FGFR1 H19 HOTAIR NEAT1
13 gastric cancer 29.2 BANCR ERBB2 FGFR2 H19 HOTAIR LINC00261
14 lung cancer 27.3 BANCR BRAF ERBB2 FGFR1 FGFR2 H19
15 hepatocellular carcinoma 26.5 BANCR DRAIC FGFR1 H19 HOTAIR HRAS
16 gastric adenocarcinoma and proximal polyposis of the stomach 12.1
17 gastric cardia adenocarcinoma 11.4
18 breast squamous cell carcinoma 11.4 ERBB2 PIK3CA TP53
19 endometrial adenocarcinoma 11.4 ERBB2 FGFR2 PTEN TP53
20 esophagus adenocarcinoma 11.4 ERBB2 PIK3CA SMAD4 TP53
21 estrogen-receptor positive breast cancer 11.4 ERBB2 FGFR2 PIK3CA TP53
22 oral cavity cancer 11.3 ERBB2 PIK3CA PTEN TP53
23 gallbladder squamous cell carcinoma 11.3 ERBB2 TP53
24 ectrodactyly, ectodermal dysplasia, and cleft lip/palate syndrome 3 11.3 PIK3CA PTEN TP53
25 mixed cell type cancer 11.3 ERBB2 HRAS TP53
26 sporadic breast cancer 11.3 ERBB2 PTEN TP53
27 ovary adenocarcinoma 11.3 ERBB2 HRAS TP53
28 ovarian clear cell carcinoma 11.3 PIK3CA PTEN TP53
29 rare adenocarcinoma of the breast 11.3 PIK3CA TP53
30 ovarian cancer 1 11.3 ERBB2 HRAS PIK3CA TP53
31 malignant ovarian surface epithelial-stromal neoplasm 11.3 ERBB2 HRAS PIK3CA TP53
32 ovary epithelial cancer 11.3 ERBB2 HRAS PIK3CA TP53
33 serous cystadenocarcinoma 11.3 ERBB2 HRAS PIK3CA TP53
34 thyroid hurthle cell adenoma 11.3 PIK3CA PTEN
35 cystadenocarcinoma 11.3 ERBB2 HRAS PIK3CA TP53
36 transitional cell carcinoma 11.3 ERBB2 HRAS PTEN TP53
37 breast carcinoma in situ 11.2 ERBB2 FGFR1 TP53
38 prostate squamous cell carcinoma 11.2 HRAS PIK3CA TP53
39 adult hepatocellular carcinoma 11.2 PIK3CA TP53
40 female reproductive organ cancer 11.2 ERBB2 HRAS PIK3CA PTEN TP53
41 respiratory system cancer 11.2 ERBB2 HRAS PIK3CA PTEN TP53
42 adenosquamous cell lung carcinoma 11.2 ERBB2 HRAS PIK3CA
43 biliary tract neoplasm 11.2 HRAS SMAD4 TP53
44 breast adenocarcinoma 11.2 ERBB2 H19 PIK3CA TP53
45 small cell cancer of the lung 11.2 HOTAIR PIK3CA PTEN TP53
46 adenoid cystic carcinoma 11.2 ERBB2 HRAS PIK3CA PTEN TP53
47 glioblastoma multiforme 11.2 ERBB2 PIK3CA PTEN TP53
48 gastric cancer, hereditary diffuse 11.2
49 bent bone dysplasia syndrome 11.2 ERBB2 FGFR2
50 uterine carcinosarcoma 11.2 ERBB2 FGFR2 HRAS PIK3CA PTEN TP53

Graphical network of the top 20 diseases related to Gastric Adenocarcinoma:



Diseases related to Gastric Adenocarcinoma

Symptoms & Phenotypes for Gastric Adenocarcinoma

UMLS symptoms related to Gastric Adenocarcinoma:


dyspepsia

GenomeRNAi Phenotypes related to Gastric Adenocarcinoma according to GeneCards Suite gene sharing:

26 (show all 12)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 9.98 PIK3CA HRAS
2 Decreased viability GR00221-A-1 9.98 PIK3CA FGFR1 RAF1 HRAS NRAS
3 Decreased viability GR00221-A-2 9.98 PIK3CA FGFR1 RAF1 HRAS
4 Decreased viability GR00221-A-3 9.98 HRAS NRAS
5 Decreased viability GR00221-A-4 9.98 PIK3CA
6 Decreased viability GR00231-A 9.98 RAF1
7 Decreased viability GR00301-A 9.98 RAF1
8 Decreased viability GR00402-S-2 9.98 PIK3CA FGFR1 RAF1 HRAS NRAS
9 Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance GR00210-A 9.72 PTEN ERBB2 FGFR2 HRAS NRAS
10 Decreased human cytomegalovirus (HCMV) strain AD169 replication GR00248-A 9.65 BRAF RAF1 FGFR1 FGFR2 MAP2K2
11 Decreased sensitivity to paclitaxel GR00112-A-0 9.16 PTEN SMAD4
12 Increased cell death HMECs cells GR00103-A-0 9.1 PTEN RAF1 FGFR1 TP53 MAP2K2 PIK3CA

MGI Mouse Phenotypes related to Gastric Adenocarcinoma:

46 (show all 21)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.38 FGFR2 ERBB2 MAP2K2 BRAF FGFR1 NRAS
2 cardiovascular system MP:0005385 10.37 FGFR2 ERBB2 MAP2K2 BRAF FGFR1 NRAS
3 endocrine/exocrine gland MP:0005379 10.33 FGFR2 ERBB2 MAP2K2 BRAF FGFR1 NRAS
4 cellular MP:0005384 10.32 ERBB2 FGFR2 MAP2K2 BRAF FGFR1 NRAS
5 growth/size/body region MP:0005378 10.31 ERBB2 FGFR2 MAP2K2 BRAF FGFR1 HRAS
6 homeostasis/metabolism MP:0005376 10.29 FGFR1 HRAS ERBB2 MAP2K2 FGFR2 BRAF
7 craniofacial MP:0005382 10.27 FGFR2 MAP2K2 BRAF FGFR1 NRAS HRAS
8 digestive/alimentary MP:0005381 10.27 FGFR2 ERBB2 MAP2K2 BRAF FGFR1 NRAS
9 integument MP:0010771 10.27 FGFR2 MAP2K2 BRAF FGFR1 NRAS HRAS
10 embryo MP:0005380 10.26 FGFR2 ERBB2 BRAF FGFR1 NRAS PIK3CA
11 neoplasm MP:0002006 10.14 FGFR2 MAP2K2 BRAF NRAS HRAS ERBB2
12 muscle MP:0005369 10.09 FGFR2 ERBB2 BRAF FGFR1 PIK3CA RAF1
13 normal MP:0002873 10.06 FGFR2 ERBB2 MAP2K2 BRAF FGFR1 NRAS
14 limbs/digits/tail MP:0005371 10.02 ERBB2 FGFR2 FGFR1 NRAS PTEN SMAD4
15 hearing/vestibular/ear MP:0005377 10 FGFR2 MAP2K2 BRAF FGFR1 RAF1 TP53
16 liver/biliary system MP:0005370 10 FGFR2 BRAF NRAS PTEN RAF1 TP53
17 no phenotypic analysis MP:0003012 9.91 HRAS FGFR2 FGFR1 NRAS PIK3CA RAF1
18 skeleton MP:0005390 9.73 ERBB2 FGFR2 MAP2K2 BRAF FGFR1 NRAS
19 renal/urinary system MP:0005367 9.7 FGFR2 BRAF FGFR1 HRAS PTEN TP53
20 pigmentation MP:0001186 9.65 FGFR2 BRAF NRAS PTEN TP53
21 vision/eye MP:0005391 9.28 FGFR2 MAP2K2 BRAF FGFR1 NRAS PTEN

Drugs & Therapeutics for Gastric Adenocarcinoma

FDA approved drugs:

# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Taxotere 18 49 DOCETAXEL Rhone Poulenc Rorer May 1996

Drugs for Gastric Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 207)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fluorouracil Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-21-8 3385
2
Irinotecan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 97682-44-5, 100286-90-6 60838
3
Levoleucovorin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 68538-85-2
4
Oxaliplatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 61825-94-3 5310940 9887054 43805 6857599
5
Capecitabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 154361-50-9 60953
6
Trastuzumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 180288-69-1 9903
7
Rabeprazole Approved, Investigational Phase 4 117976-89-3 5029
8
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
9
Iron Approved Phase 4 7439-89-6 23925
10
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 59-30-3 6037
11
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1 58-05-9 143 6006
12
Camptothecin Experimental Phase 4,Phase 2,Phase 1 7689-03-4
13 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1
14 Micronutrients Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
15 Trace Elements Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
16 Antidotes Phase 4,Phase 3,Phase 2,Phase 1
17 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1
18 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1
19 Antineoplastic Agents, Phytogenic Phase 4,Phase 3,Phase 2,Phase 1
20 Calcium, Dietary Phase 4,Phase 3,Phase 2,Phase 1
21 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1
22 Protective Agents Phase 4,Phase 3,Phase 2,Phase 1
23 topoisomerase I inhibitors Phase 4,Phase 3,Phase 2,Phase 1
24 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
25 Vitamin B Complex Phase 4,Phase 3,Phase 2,Phase 1
26 Vitamins Phase 4,Phase 3,Phase 2,Phase 1
27 Antacids Phase 4,Phase 3,Phase 1
28 Anti-Ulcer Agents Phase 4,Phase 3,Phase 1
29 Gastrointestinal Agents Phase 4,Phase 3,Phase 1
30 Proton Pump Inhibitors Phase 4
31 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
32 Hematinics Phase 4,Phase 3,Phase 2,Phase 1
33 Ferric Compounds Phase 4
34 Folate Nutraceutical Phase 4,Phase 3,Phase 1,Phase 2
35 Vitamin B9 Nutraceutical Phase 4,Phase 3,Phase 1,Phase 2
36
Cisplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 15663-27-1 84093 441203 2767
37
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
38
Docetaxel Approved, Investigational Phase 3,Phase 2,Phase 1 114977-28-5 148124
39
Epirubicin Approved Phase 3,Phase 2,Phase 1,Not Applicable 56420-45-2 41867
40
Tegafur Approved, Investigational Phase 3,Phase 2 17902-23-7 5386
41
Pancrelipase Approved, Investigational Phase 3,Phase 2,Phase 1 53608-75-6
42
Bevacizumab Approved, Investigational Phase 2, Phase 3,Phase 1 216974-75-3
43
Ramucirumab Approved, Investigational Phase 3,Phase 2,Phase 1 947687-13-0
44
Midazolam Approved, Illicit Phase 3 59467-70-8 4192
45
Cetuximab Approved Phase 3,Phase 2,Phase 1 205923-56-4 56842117 2333
46
Floxuridine Approved Phase 3,Phase 2 50-91-9 5790
47
Everolimus Approved Phase 3,Phase 2,Phase 1 159351-69-6 6442177
48
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 22916-47-8 4189
49
Sirolimus Approved, Investigational Phase 3,Phase 2,Phase 1 53123-88-9 5284616 6436030 46835353
50
Pertuzumab Approved Phase 2, Phase 3 145040-37-5, 380610-27-5 2540

Interventional clinical trials:

(show top 50) (show all 360)
# Name Status NCT ID Phase Drugs
1 Effects of Oral Rabeprazole on the Prevention of Ulcer Bleeding Following Endoscopic Mucosal Resection Completed NCT00844675 Phase 4 rabeprazole;placebo
2 Dual Therapy With High Doses of Ilaprazole and Amoxicillin for Helicobacter Pylori Infection Completed NCT02401477 Phase 4 Ilaprazole + Amoxicillin
3 Study of Apatinib Tablets in the Treatment of Advanced or Metastatic Gastric Cancer Recruiting NCT02426034 Phase 4 Apatinib
4 Iron Replacement in Oesophagogastric Neoplasia Recruiting NCT01927328 Phase 4 Iron isomaltoside 1000
5 Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer Recruiting NCT02366819 Phase 4 Oxaliplatin;Leucovorin Calcium;Irinotecan Hydrochloride;Fluorouracil
6 Pharmacokinetic Study of Capecitabine After Total Gastrectomy for Stomach Adenocarcinoma Terminated NCT00871273 Phase 4 capecitabine
7 A Study of Herceptin (Trastuzumab) in Combination With Standard Chemotherapy in Patients With HER Positive Metastatic Gastric Cancer Terminated NCT01260194 Phase 4 trastuzumab [Herceptin]
8 Paclitaxel Plus Capecitabine With Capecitabine Maintenance Treatment in Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction Unknown status NCT01015339 Phase 3 Paclitaxel;capecitabine;capecitabine;cisplatin
9 Taxanes or Platinum in Combination With Capecitabine Followed by Capecitabine Alone as First Line Treatment for Patients With Advanced Adenocarcinoma of Stomach or Esophagogastric Junction Unknown status NCT01468389 Phase 3 Capecitabine;capecitabine
10 SOX Regimen as Neoadjuvant Chemotherapy for AJCC Stage II-III Gastric Cancer Unknown status NCT01583361 Phase 3 Oxaliplatin+S-1;Adjuvant Oxaliplatin/S-1(SOX)
11 Docetaxel and S1 (DS) Versus S1 and Cisplatin (SP) in Curatively Resected Stage IIIB/IV Gastric Cancer Unknown status NCT01283217 Phase 3 DS;SP
12 Trial of Adjuvant XELOX Chemotherapy and Concurrent Capecitabine and Radiotherapy for Resected Gastric Carcinoma Unknown status NCT01711242 Phase 3 Capecitabine;Oxaliplatin
13 Apatinib as Maintenance Therapy After First Line Treatment in Locally Advanced or Metastatic Gastric Cancer Unknown status NCT02537171 Phase 3 apatinib
14 Surgery With or Without Combination Chemotherapy in Treating Patients With Cancer of the Esophagus Unknown status NCT00002883 Phase 3 cisplatin;fluorouracil
15 Chemotherapy and Radiation Therapy After Surgery in Treating Patients With Stomach or Esophageal Cancer Unknown status NCT00052910 Phase 3 cisplatin;epirubicin hydrochloride;fluorouracil;leucovorin calcium
16 Intergroup Trial of Adjuvant Chemotherapy in Adenocarcinoma of the Stomach Completed NCT01640782 Phase 3 Irinotecan, Leucovorin, 5-Fluorouracil, Docetaxel, Cisplatin;Leucovorin, 5-Fluorouracil
17 A Study of Paclitaxel With or Without Ramucirumab (IMC-1211B) in Metastatic Gastric Adenocarcinoma Completed NCT01170663 Phase 3 Placebo;Paclitaxel
18 Phase III Randomized Trial of Adjuvant XP Chemotherapy and XP/RT for Resected Gastric Adenocarcinoma Completed NCT00323830 Phase 3 Capecitabine, cisplatin, Radiotherapy (+/-)
19 Covered Versus Uncovered Self-expandable Metallic Stents for Malignant Gastric Outlet Obstruction Completed NCT01646476 Phase 3
20 Erbitux in Combination With Xeloda and Cisplatin in Advanced Esophago-gastric Cancer Completed NCT00678535 Phase 3 Cetuximab;Capecitabine;Cisplatin
21 Symptom Control With or Without Docetaxel in Treating Patients With Relapsed Esophageal Cancer or Stomach Cancer Completed NCT00978549 Phase 3 docetaxel;steroid therapy
22 Trial of Adjuvant Chemotherapy for Gastric Cancer Completed NCT00296335 Phase 3 Mitomycin, doxifluridine and cisplatin;Mitomycin and doxifluridine
23 A Study of Capecitabine (Xeloda) in Combination Chemotherapy Versus Surgery Alone in Participants With Gastric Cancer Completed NCT02560974 Phase 3 Capecitabine;Oxaliplatin
24 Trial of Adjuvant Chemotherapy for Gastric Cancer Completed NCT00296322 Phase 3 cisplatin, mitomycin-C, doxifluridine
25 Capecitabine and Oxaliplatin Adjuvant Study in Stomach Cancer Completed NCT00411229 Phase 3 Capecitabine;Oxaliplatin
26 Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Participants With Gastric Cancer and Adenocarcinoma Completed NCT00917384 Phase 3 Placebo
27 Metastatic Gastric Cancer FFCD 03-07 Completed NCT00374036 Phase 3 ECC;FOLFIRI
28 S-1 and Cisplatin in Treating Patients Who Are Undergoing Surgery for Stage III Stomach Cancer Completed NCT00182611 Phase 3 cisplatin;tegafur-gimeracil-oteracil potassium
29 A Study of Onartuzumab in Combination With mFOLFOX6 in Participants With Metastatic HER2-Negative and MET-Positive Gastroesophageal Cancer Completed NCT01662869 Phase 3 5-Fluoruracil;Folinic acid;Onartuzumab;Oxaliplatin;Placebo
30 Impact of Roux-En-Y Pouch Reconstruction Compared With Conventional Roux-En-Y Reconstruction on Health-Related Quality of Life in Patients Undergoing Total Gastrectomy for Adenocarcinoma Completed NCT01491698 Phase 3
31 Surgery With or Without Combination Chemotherapy in Treating Patients With Stomach Cancer Completed NCT00002615 Phase 3 cisplatin;epirubicin hydrochloride;fluorouracil
32 Vaccine Therapy Plus Chemotherapy in Treating Patients With Metastatic or Locally Recurrent Stomach Cancer or Esophageal Cancer Completed NCT00020787 Phase 3 cisplatin;fluorouracil
33 Safety and Efficacy of RAD001 (Everolimus) Monotherapy Plus Best Supportive Care in Patients With Advanced Gastric Cancer (AGC) Completed NCT00879333 Phase 3 Everolimus;Everolimus placebo;Best Supportive Care (BSC)
34 S-1+Oxaliplatin vs.S-1+Cisplatin First-line Treatment of Advanced or Recurrent Non-intestinal Type Gastric Adenocarcinoma Patients Recruiting NCT01824459 Phase 3 S-1;Oxaliplatin;Cisplatin
35 Preoperative Concurrent Chemoradiotherapy for Locally Advanced Gastroesophageal Junction or Upper Gastric Adenocarcinoma Recruiting NCT02193594 Phase 2, Phase 3 Adjuvant chemotherapy
36 D2 Resection and HIPEC (Hyperthermic Intraperitoneal Chemoperfusion) in Locally Advanced Gastric Carcinoma Recruiting NCT01882933 Phase 3 HIPEC (Hyperthermic Intraperitoneal Chemoperfusion) with oxaliplatin
37 Phase III Study to Compare Perioperative Chemotherapy of Oxaliplatin Combined With S-1(SOX) Versus SOX or Oxaliplatin With Capecitabine (XELOX) as Post-operative Chemotherapy in Locally Advanced Gastric Adenocarcinoma With D2 Dissection Recruiting NCT01534546 Phase 3 Oxaliplatin capecitabine;Oxaliplatin S-1;Oxaliplatin S-1
38 Chemotherapy Alone vs. Chemotherapy + Surgical Resection in Patients With Limited-metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction Recruiting NCT02578368 Phase 3 5-Fluorouracil;Leucovorin;Oxaliplatin;Docetaxel;Trastuzumab;sodium folinate
39 Efficacy of HIPEC in the Treatment of Patients With Locally Advanced Gastric Cancer Recruiting NCT02240524 Phase 3
40 Neoadjuvant SLOT Versus SOX in Patients With Locally Advanced, Resectable Gastric/Esophagogastric Junction (EGJ) Cancer Recruiting NCT02512380 Phase 3 Docetaxel;oxaliplatin;s1;oxaliplatin;s1
41 A Clinical Trial of D1+ Versus D2 Distal Gastrectomy for Stage IB & II Advanced Gastric Cancer Recruiting NCT02144727 Phase 3
42 FLOT vs. FLOT/Herceptin/Pertuzumab for Perioperative Therapy of HER-2 Expressing Gastric or GEJ Cancer Recruiting NCT02581462 Phase 2, Phase 3 FLOT alone
43 Phase III Randomized Trial of Adjuvant Chemotherapy With S-1 vs S-1/Oxaliplatin ± Radiotherapy for Completely Resected Gastric Adenocarcinoma : The ARTIST II Trial Recruiting NCT01761461 Phase 3 TS-1, oxaliplatin
44 Efficacy and Safety Trial of Apatinib Plus Best Supportive Care Compared to Placebo Plus Best Supportive Care in Patients With Gastric Cancer Recruiting NCT03042611 Phase 3 Apatinib
45 Phase 3 Study of Xelox Followed by Maintenance Capecitabine in the Advanced Gastric Cancer Recruiting NCT02289547 Phase 3 Capecitabine
46 A Study of Paclitaxel With or Without Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Cancer Recruiting NCT02898077 Phase 3 Ramucirumab;Paclitaxel;Placebo
47 Preoperative Stomach Cancer Induction Chemotherapy and Radiation Therapy Recruiting NCT03223740 Phase 3
48 Adjuvant Capecitabine Versus Observation Alone in Curatively Resected Stage IB Gastric Cancer Recruiting NCT01917552 Phase 3 capecitabine
49 A Study to Assess the Efficacy of IMAB362 Plus mFOLFOX6 Compared With Placebo Plus mFOLFOX6 as First-line Treatment of Subjects With Claudin (CLDN) 18.2 Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junct Recruiting NCT03504397 Phase 3 IMAB362;placebo;oxaliplatin;leucovorin;fluorouracil
50 Preoperative Concurrent Chemoradiotherapy for Potentially Resectable Adenocarcinoma of the Esophagogastric Junction Recruiting NCT01962246 Phase 2, Phase 3 Oxaliplatin; Capecitabine

Search NIH Clinical Center for Gastric Adenocarcinoma

Genetic Tests for Gastric Adenocarcinoma

Anatomical Context for Gastric Adenocarcinoma

MalaCards organs/tissues related to Gastric Adenocarcinoma:

41
Lymph Node, Liver, Bone, Lung, Eye, Skin, Colon

Publications for Gastric Adenocarcinoma

Articles related to Gastric Adenocarcinoma:

(show top 50) (show all 1135)
# Title Authors Year
1
Collision tumor consisting of a colorectal adenocarcinoma and dissemination of a gastric adenocarcinoma. ( 29326826 )
2018
2
Vimentin-positive gastric adenocarcinoma arising in a hyperplastic polyp. ( 29417386 )
2018
3
<i>Helicobacter pylori</i> eradication treatment and the risk of gastric adenocarcinoma in a Western population. ( 29382776 )
2018
4
Combination of arginine, glutamine, and omega-3 fatty acid supplements for perioperative enteral nutrition in surgical patients with gastric adenocarcinoma or gastrointestinal stromal tumor (GIST): A prospective, randomized, double-blind study. ( 29848836 )
2018
5
A Six-Gene Signature Predicts Clinical Outcome of Gastric Adenocarcinoma. ( 29848271 )
2018
6
Gastric adenocarcinoma expressing human epidermal growth factor receptor in South Asian population. ( 29806596 )
2018
7
Effects of carvacrol on human fibroblast (WS-1) and gastric adenocarcinoma (AGS) cells in vitro and on Wistar rats in vivo. ( 29442269 )
2018
8
Subhyaloid hemorrhage as the first presenting sign of gastric adenocarcinoma. ( 29310953 )
2018
9
Reduced Expression of Deubiquitinase USP33 Is Associated with Tumor Progression and Poor Prognosis of Gastric Adenocarcinoma. ( 29802710 )
2018
10
Tumor of the Turkish saddle with endocrine disorders as the first manifestation of gastric adenocarcinoma. ( 29385110 )
2018
11
Geographic variation in molecular subtype for gastric adenocarcinoma. ( 29960981 )
2018
12
Effect of total number of harvested lymph nodes on survival outcomes after curative resection for gastric adenocarcinoma: findings from an eastern high-volume gastric cancer center. ( 29329569 )
2018
13
Orally administered brown seaweed-derived I^-glucan effectively restrained development of gastric dysplasia in A4gnt KO mice that spontaneously develop gastric adenocarcinoma. ( 29763881 )
2018
14
<i>Celastrus orbiculatus</i> extracts induce apoptosis and inhibit invasion by targeting the maspin gene in human gastric adenocarcinoma cells. ( 29387218 )
2018
15
PD-1 and PD-L1 Up-regulation Promotes T-cell Apoptosis in Gastric Adenocarcinoma. ( 29599324 )
2018
16
Sequential spinal and intracranial dural metastases in gastric adenocarcinoma: A case report. ( 29434454 )
2018
17
Quercetin Suppresses CYR61-Mediated Multidrug Resistance in Human Gastric Adenocarcinoma AGS Cells. ( 29364834 )
2018
18
2,4-Di-tert-butylphenol, a potential HDAC6 inhibitor, induces senescence and mitotic catastrophe in human gastric adenocarcinoma AGS cells. ( 29427610 )
2018
19
Immuno-Histochemical Assessment of HER2NEU Expression in Gastric Adenocarcinoma in North Karnataka, India ( 29802704 )
2018
20
Neoplastic Lesions of Gastric Adenocarcinoma and Proximal Polyposis Syndrome (GAPPS) Are Gastric Phenotype. ( 29112017 )
2018
21
Martrilin-3 (MATN3) Overexpression in Gastric Adenocarcinoma and its Prognostic Significance. ( 29343680 )
2018
22
Effects of miR-21 on proliferation and apoptosis in human gastric adenocarcinoma cells. ( 29403555 )
2018
23
Expression and prognostic significance of human epidermal growth factor receptors 1, 2 and 3 in oesophageal and gastric adenocarcinomas preneoadjuvant and postneoadjuvant treatment. ( 29138285 )
2018
24
Expression and prognostic value of cell-cycle-associated genes in gastric adenocarcinoma. ( 29884122 )
2018
25
Efficacy after preoperative capecitabine and oxaliplatin (XELOX) versus docetaxel, oxaliplatin and S1 (DOS) in patients with locally advanced gastric adenocarcinoma: a propensity score matching analysis. ( 29954358 )
2018
26
Potentially curable gastric adenocarcinoma treated without surgery. ( 29859338 )
2018
27
l-asparaginase induces intrinsic mitochondrial-mediated apoptosis in human gastric adenocarcinoma cells and impedes tumor progression. ( 29966654 )
2018
28
First report of an Asian family with gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS) revealed with the germline mutation of the APC exon 1B promoter region. ( 29968043 )
2018
29
GalNAc-T15 in gastric adenocarcinoma: Characterization according to tissue architecture and cellular location. ( 29943957 )
2018
30
Next-generation sequencing analysis for gastric adenocarcinoma with enteroblastic differentiation: emphasis on the relationship with hepatoid adenocarcinoma. ( 29751042 )
2018
31
CURRENT STATUS OF THE MULTIDISCIPLINARY TREATMENT OF GASTRIC ADENOCARCINOMA. ( 29972401 )
2018
32
Comparative Molecular Analyses of Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, and Gastric Adenocarcinoma. ( 29866946 )
2018
33
The association among HER2, MET and FOXP3 expression and tumor regression grading in gastric adenocarcinoma. ( 29696715 )
2018
34
A challenging diagnosis: Case report of oral metastasis from gastric adenocarcinoma mimicking pyogenic granuloma. ( 29595701 )
2018
35
Clinical usefulness of extending the proximal margin in total gastrectomies for gastric adenocarcinoma. ( 29753577 )
2018
36
Cancer cell-derived von Willebrand factor enhanced metastasis of gastric adenocarcinoma. ( 29362409 )
2018
37
COX-2 gene expression and methylation profile in Sapajus apella as an experimental model for gastric adenocarcinoma. ( 29767663 )
2018
38
Clinical Evaluation of Serum Tumor Markers in the Diagnosis of Gastric Adenocarcinoma Staging and Grading. ( 29806060 )
2018
39
Prevalence of multiple infections and the risk of gastric adenocarcinoma development at earlier age. ( 29880208 )
2018
40
Expression and prognostic significance of cyclin-dependent kinase inhibitor 1A in patients with resected gastric adenocarcinoma. ( 29344191 )
2017
41
Prognostic significance of autophagy-related proteins expression in resected human gastric adenocarcinoma. ( 28224423 )
2017
42
A retrospective analysis of ramucirumab monotherapy in previously treated Japanese patients with advanced or metastatic gastric adenocarcinoma. ( 28913565 )
2017
43
Iodine Concentration in Spectral CT: Assessment of Prognostic Determinants in Patients With Gastric Adenocarcinoma. ( 28871809 )
2017
44
Overexpression of HER-2 Protein is a High-Risk Factor for Patients with Surgically-Resected Stage T3 Gastric Adenocarcinoma. ( 28164509 )
2017
45
Malignant acanthosis nigricans: an early diagnostic clue for gastric adenocarcinoma. ( 29178944 )
2017
46
Expression and potential roles of sodium-potassium ATPase and E-cadherin in human gastric adenocarcinoma. ( 28832634 )
2017
47
Subacute cutaneous lupus erythematosus - paraneoplastic to gastric adenocarcinoma? ( 28421344 )
2017
48
Long-term Trends in Primary Sites of Gastric Adenocarcinoma in Japan and the United States. ( 28819392 )
2017
49
Role of Rac1 Pathway in Epithelial-to-Mesenchymal Transition and Cancer Stem-like Cell Phenotypes in Gastric Adenocarcinoma. ( 28461325 )
2017
50
Differentially regulated ADAMTS1, 8, and 18 in gastric adenocarcinoma. ( 28814085 )
2017

Variations for Gastric Adenocarcinoma

ClinVar genetic disease variations for Gastric Adenocarcinoma:

6
(show top 50) (show all 705)
# Gene Variation Type Significance SNP ID Assembly Location
1 PTEN NM_000314.6(PTEN): c.389G> A (p.Arg130Gln) single nucleotide variant Pathogenic rs121909229 GRCh37 Chromosome 10, 89692905: 89692905
2 PTEN NM_000314.6(PTEN): c.389G> A (p.Arg130Gln) single nucleotide variant Pathogenic rs121909229 GRCh38 Chromosome 10, 87933148: 87933148
3 MAP2K2 NM_030662.3(MAP2K2): c.169T> G (p.Phe57Val) single nucleotide variant Pathogenic rs121434498 GRCh37 Chromosome 19, 4117551: 4117551
4 MAP2K2 NM_030662.3(MAP2K2): c.169T> G (p.Phe57Val) single nucleotide variant Pathogenic rs121434498 GRCh38 Chromosome 19, 4117553: 4117553
5 SMAD4 NM_005359.5(SMAD4): c.1081C> T (p.Arg361Cys) single nucleotide variant Pathogenic rs80338963 GRCh37 Chromosome 18, 48591918: 48591918
6 SMAD4 NM_005359.5(SMAD4): c.1081C> T (p.Arg361Cys) single nucleotide variant Pathogenic rs80338963 GRCh38 Chromosome 18, 51065548: 51065548
7 SMAD4 NM_005359.5(SMAD4): c.1157G> A (p.Gly386Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121912580 GRCh37 Chromosome 18, 48593406: 48593406
8 SMAD4 NM_005359.5(SMAD4): c.1157G> A (p.Gly386Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121912580 GRCh38 Chromosome 18, 51067036: 51067036
9 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic rs121912651 GRCh37 Chromosome 17, 7577539: 7577539
10 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic rs121912651 GRCh38 Chromosome 17, 7674221: 7674221
11 TP53 NM_000546.5(TP53): c.733G> T (p.Gly245Cys) single nucleotide variant Pathogenic rs28934575 GRCh37 Chromosome 17, 7577548: 7577548
12 TP53 NM_000546.5(TP53): c.733G> T (p.Gly245Cys) single nucleotide variant Pathogenic rs28934575 GRCh38 Chromosome 17, 7674230: 7674230
13 TP53 NM_000546.5(TP53): c.725G> A (p.Cys242Tyr) single nucleotide variant Pathogenic rs121912655 GRCh37 Chromosome 17, 7577556: 7577556
14 TP53 NM_000546.5(TP53): c.725G> A (p.Cys242Tyr) single nucleotide variant Pathogenic rs121912655 GRCh38 Chromosome 17, 7674238: 7674238
15 TP53 NM_000546.5(TP53): c.734G> A (p.Gly245Asp) single nucleotide variant Pathogenic rs121912656 GRCh37 Chromosome 17, 7577547: 7577547
16 TP53 NM_000546.5(TP53): c.734G> A (p.Gly245Asp) single nucleotide variant Pathogenic rs121912656 GRCh38 Chromosome 17, 7674229: 7674229
17 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 GRCh37 Chromosome 17, 7577538: 7577538
18 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 GRCh38 Chromosome 17, 7674220: 7674220
19 TP53 NM_000546.5(TP53): c.814G> T (p.Val272Leu) single nucleotide variant Likely pathogenic rs121912657 GRCh37 Chromosome 17, 7577124: 7577124
20 TP53 NM_000546.5(TP53): c.814G> T (p.Val272Leu) single nucleotide variant Likely pathogenic rs121912657 GRCh38 Chromosome 17, 7673806: 7673806
21 TP53 NM_000546.5(TP53): c.844C> T (p.Arg282Trp) single nucleotide variant Pathogenic rs28934574 GRCh37 Chromosome 17, 7577094: 7577094
22 TP53 NM_000546.5(TP53): c.844C> T (p.Arg282Trp) single nucleotide variant Pathogenic rs28934574 GRCh38 Chromosome 17, 7673776: 7673776
23 TP53 NM_000546.5(TP53): c.733G> A (p.Gly245Ser) single nucleotide variant Pathogenic rs28934575 GRCh37 Chromosome 17, 7577548: 7577548
24 TP53 NM_000546.5(TP53): c.733G> A (p.Gly245Ser) single nucleotide variant Pathogenic rs28934575 GRCh38 Chromosome 17, 7674230: 7674230
25 TP53 NM_000546.5(TP53): c.818G> A (p.Arg273His) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 GRCh37 Chromosome 17, 7577120: 7577120
26 TP53 NM_000546.5(TP53): c.818G> A (p.Arg273His) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 GRCh38 Chromosome 17, 7673802: 7673802
27 TP53 NM_000546.5(TP53): c.451C> A (p.Pro151Thr) single nucleotide variant Likely pathogenic rs28934874 GRCh37 Chromosome 17, 7578479: 7578479
28 TP53 NM_000546.5(TP53): c.451C> A (p.Pro151Thr) single nucleotide variant Likely pathogenic rs28934874 GRCh38 Chromosome 17, 7675161: 7675161
29 TP53 NM_000546.5(TP53): c.451C> T (p.Pro151Ser) single nucleotide variant Pathogenic/Likely pathogenic rs28934874 GRCh37 Chromosome 17, 7578479: 7578479
30 TP53 NM_000546.5(TP53): c.451C> T (p.Pro151Ser) single nucleotide variant Pathogenic/Likely pathogenic rs28934874 GRCh38 Chromosome 17, 7675161: 7675161
31 TP53 NM_000546.5(TP53): c.659A> C (p.Tyr220Ser) single nucleotide variant Pathogenic rs121912666 GRCh37 Chromosome 17, 7578190: 7578190
32 TP53 NM_000546.5(TP53): c.659A> C (p.Tyr220Ser) single nucleotide variant Pathogenic rs121912666 GRCh38 Chromosome 17, 7674872: 7674872
33 HRAS NM_005343.3(HRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
34 HRAS NM_005343.3(HRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs104894229 GRCh38 Chromosome 11, 534289: 534289
35 HRAS NM_005343.3(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic rs104894230 GRCh37 Chromosome 11, 534288: 534288
36 HRAS NM_005343.3(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic rs104894230 GRCh38 Chromosome 11, 534288: 534288
37 HRAS NM_005343.3(HRAS): c.436G> A (p.Ala146Thr) single nucleotide variant Pathogenic/Likely pathogenic rs104894231 GRCh38 Chromosome 11, 533467: 533467
38 HRAS NM_005343.3(HRAS): c.37G> T (p.Gly13Cys) single nucleotide variant Pathogenic rs104894228 GRCh37 Chromosome 11, 534286: 534286
39 HRAS NM_005343.3(HRAS): c.37G> T (p.Gly13Cys) single nucleotide variant Pathogenic rs104894228 GRCh38 Chromosome 11, 534286: 534286
40 HRAS NM_005343.3(HRAS): c.436G> A (p.Ala146Thr) single nucleotide variant Pathogenic/Likely pathogenic rs104894231 GRCh37 Chromosome 11, 533467: 533467
41 HRAS NM_005343.3(HRAS): c.437C> T (p.Ala146Val) single nucleotide variant Likely pathogenic rs121917759 GRCh37 Chromosome 11, 533466: 533466
42 HRAS NM_005343.3(HRAS): c.437C> T (p.Ala146Val) single nucleotide variant Likely pathogenic rs121917759 GRCh38 Chromosome 11, 533466: 533466
43 HRAS NM_005343.3(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
44 HRAS NM_005343.3(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic rs104894229 GRCh38 Chromosome 11, 534289: 534289
45 FGFR2 NM_022970.3(FGFR2): c.755C> G (p.Ser252Trp) single nucleotide variant Pathogenic rs79184941 GRCh37 Chromosome 10, 123279677: 123279677
46 FGFR2 NM_022970.3(FGFR2): c.755C> G (p.Ser252Trp) single nucleotide variant Pathogenic rs79184941 GRCh38 Chromosome 10, 121520163: 121520163
47 PIK3CA NM_006218.3(PIK3CA): c.3140A> G (p.His1047Arg) single nucleotide variant Pathogenic rs121913279 GRCh37 Chromosome 3, 178952085: 178952085
48 PIK3CA NM_006218.3(PIK3CA): c.3140A> G (p.His1047Arg) single nucleotide variant Pathogenic rs121913279 GRCh38 Chromosome 3, 179234297: 179234297
49 PIK3CA NM_006218.3(PIK3CA): c.3140A> T (p.His1047Leu) single nucleotide variant Pathogenic rs121913279 GRCh37 Chromosome 3, 178952085: 178952085
50 PIK3CA NM_006218.3(PIK3CA): c.3140A> T (p.His1047Leu) single nucleotide variant Pathogenic rs121913279 GRCh38 Chromosome 3, 179234297: 179234297

Cosmic variations for Gastric Adenocarcinoma:

9
(show top 50) (show all 52)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM6982918 YES1 skin,eye,carcinoma,NS c.851G>A p.G284E 18:743289-743289 3
2 COSM4736805 TSC1 skin,eye,carcinoma,NS c.2065C>T p.R689C 9:132903794-132903794 3
3 COSM6971614 TRAF7 skin,eye,carcinoma,NS c.349G>A p.E117K 16:2171264-2171264 3
4 COSM45444 TP53 skin,eye,carcinoma,NS c.587G>T p.R196L 17:7674944-7674944 3
5 COSM44126 TP53 skin,eye,carcinoma,NS c.507G>A p.M169I 17:7675105-7675105 3
6 COSM6937552 TP53 skin,eye,carcinoma,NS c.859G>C p.E287Q 17:7673761-7673761 3
7 COSM10724 TP53 skin,eye,carcinoma,NS c.839G>C p.R280T 17:7673781-7673781 3
8 COSM43583 TP53 skin,eye,carcinoma,NS c.425C>T p.P142L 17:7675187-7675187 3
9 COSM4462891 STK40 skin,eye,carcinoma,NS c.1265C>T p.S422F 1:36341798-36341798 3
10 COSM4462893 STK40 skin,eye,carcinoma,NS c.1265C>T p.S422F 1:36341798-36341798 3
11 COSM6009093 SPEN skin,eye,carcinoma,NS c.9563C>T p.P3188L 1:15935803-15935803 3
12 COSM6982915 SOX2 skin,eye,carcinoma,NS c.237G>A p.W79* 3:181712597-181712597 3
13 COSM5538304 RNF43 skin,eye,carcinoma,NS c.866C>T p.S289F 17:58360235-58360235 3
14 COSM5468163 RAD52 skin,eye,carcinoma,NS c.779G>A p.R260Q 12:916430-916430 3
15 COSM144245 PTCH1 skin,eye,carcinoma,NS c.1585A>T p.K529* 9:95476776-95476776 3
16 COSM221754 PPP6C skin,eye,carcinoma,NS c.790C>T p.R264C 9:125149801-125149801 3
17 COSM6971613 PIK3R1 skin,eye,carcinoma,NS c.608A>G p.Y203C 5:68279707-68279707 3
18 COSM6971611 NOTCH2 skin,eye,carcinoma,NS c.4091C>T p.P1364L 1:119925725-119925725 3
19 COSM6072631 KDM5A skin,eye,carcinoma,NS c.973C>T p.P325S 12:354132-354132 3
20 COSM6982913 INPP4A skin,eye,carcinoma,NS c.407G>A p.G136E 2:98536148-98536148 3
21 COSM6982909 IKBKE skin,eye,carcinoma,NS c.537C>A p.Y179* 1:206476359-206476359 3
22 COSM498 HRAS skin,eye,carcinoma,NS c.182A>T p.Q61L 11:533874-533874 3
23 COSM732369 FBXW7 skin,eye,carcinoma,NS c.535C>T p.R179C 4:152350091-152350091 3
24 COSM6971612 CTNNB1 skin,eye,carcinoma,NS c.1420C>T p.R474* 3:41233763-41233763 3
25 COSM13828 CDKN2A skin,eye,carcinoma,NS c.149A>G p.Q50R 9:21974679-21974679 3
26 COSM4900080 BTK skin,eye,carcinoma,NS c.262G>A p.E88K 23:101371680-101371680 3
27 COSM6971615 BRIP1 skin,eye,carcinoma,NS c.1463C>T p.P488L 17:61793607-61793607 3
28 COSM6971610 BARD1 skin,eye,carcinoma,NS c.722C>T p.S241F 2:214781152-214781152 3
29 COSM6982919 AR skin,eye,carcinoma,NS c.1883G>A p.G628E 23:67686124-67686124 3
30 COSM1432255 APC skin,eye,carcinoma,NS c.3367C>T p.Q1123* 5:112838961-112838961 3
31 COSM6971616 skin,eye,carcinoma,NS c.1463C>T p.P488L 17:61793607-61793607 3
32 COSM6982911 skin,eye,carcinoma,NS c.407G>A p.G136E 2:98536148-98536148 3
33 COSM6982912 skin,eye,carcinoma,NS c.407G>A p.G136E 2:98536148-98536148 3
34 COSM6985418 skin,eye,carcinoma,NS c.149A>G p.Q50R 9:21974679-21974679 3
35 COSM254987 skin,eye,carcinoma,NS c.839G>C p.R280T 17:7673781-7673781 3
36 COSM6982921 skin,eye,carcinoma,NS c.1313G>A p.G438E 23:67686124-67686124 3
37 COSM6937553 skin,eye,carcinoma,NS c.859G>C p.E287Q 17:7673761-7673761 3
38 COSM1151204 skin,eye,carcinoma,NS c.901C>T p.R301C 9:125149801-125149801 3
39 COSM1649340 skin,eye,carcinoma,NS c.839G>C p.R280T 17:7673781-7673781 3
40 COSM4462892 skin,eye,carcinoma,NS c.1280C>T p.S427F 1:36341798-36341798 3
41 COSM732370 skin,eye,carcinoma,NS c.535C>T p.R179C 4:152350091-152350091 3
42 COSM1149858 skin,eye,carcinoma,NS c.181C>T p.R61C 4:152350091-152350091 3
43 COSM732371 skin,eye,carcinoma,NS c.295C>T p.R99C 4:152350091-152350091 3
44 COSM6072630 skin,eye,carcinoma,NS c.973C>T p.P325S 12:354132-354132 3
45 COSM6982920 skin,eye,carcinoma,NS c.287G>A p.G96E 23:67686124-67686124 3
46 COSM6937554 skin,eye,carcinoma,NS c.859G>C p.E287Q 17:7673761-7673761 3
47 COSM3639486 skin,eye,carcinoma,NS c.910G>A p.E304K 7:50399977-50399977 3
48 COSM6982914 skin,eye,carcinoma,NS c.407G>A p.G136E 2:98536148-98536148 3
49 COSM6985419 skin,eye,carcinoma,NS c.149A>G p.Q50R 9:21974679-21974679 3
50 COSM3733332 skin,eye,carcinoma,NS c.839G>C p.R280T 17:7673781-7673781 3

Copy number variations for Gastric Adenocarcinoma from CNVD:

7 (show all 39)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 14963 1 111600000 115900000 Gain C1orf88 Gastric adenocarcinoma
2 14964 1 111600000 115900000 Gain CHIA Gastric adenocarcinoma
3 14966 1 111600000 115900000 Gain OVGP1 Gastric adenocarcinoma
4 33992 1 51300000 56200000 Loss LRP8 Gastric adenocarcinoma
5 38160 10 1 3000000 Gain DIP2C Gastric adenocarcinoma
6 48224 10 99400000 102000000 Gain CHUK Gastric adenocarcinoma
7 48225 10 99400000 102000000 Gain CWF19L1 Gastric adenocarcinoma
8 48226 10 99400000 102000000 Gain SPFH1 Gastric adenocarcinoma
9 48323 11 1 21600000 Gain ST5 Gastric adenocarcinoma
10 66124 12 25358179 25403863 Amplification KRAS Gastric adenocarcinoma
11 80193 13 86500000 88800000 Loss SLITRK5 Gastric adenocarcinoma
12 81497 14 103000000 106368585 Loss IGHV3-22 Gastric adenocarcinoma
13 92520 15 41400000 42700000 Loss CAPN3 Gastric adenocarcinoma
14 92521 15 41400000 42700000 Loss GANC Gastric adenocarcinoma
15 93577 15 55800000 57100000 Gain LDHAL6B Gastric adenocarcinoma
16 93578 15 55800000 57100000 Gain MYO1E Gastric adenocarcinoma
17 97919 16 14700000 16700000 Gain PKD1P3 Gastric adenocarcinoma
18 112023 17 3773917 3814485 Loss ATP2A3 Gastric adenocarcinoma
19 112078 17 37844392 37884914 Amplification Gastric adenocarcinoma
20 112310 17 3854487 3993002 Loss ZZEF1 Gastric adenocarcinoma
21 130603 19 50000000 53800000 Gain Gastric adenocarcinoma
22 135991 12 128122223 128954165 Gain TMEM132D Gastric adenocarcinoma
23 159208 21 41400000 46944323 Loss HSF2BP Gastric adenocarcinoma
24 159209 21 41400000 46944323 Loss KIAA0179 Gastric adenocarcinoma
25 166094 3 1 3500000 Loss CNTN6 Gastric adenocarcinoma
26 169827 3 14700000 23800000 Loss UBE2E1 Gastric adenocarcinoma
27 182313 4 139500000 141700000 Loss MAML3 Gastric adenocarcinoma
28 184256 4 172200000 176600000 Loss Gastric adenocarcinoma
29 195591 5 152100000 155600000 Loss TIMD4 Gastric adenocarcinoma
30 201331 5 68400000 73300000 Gain FCHO2 Gastric adenocarcinoma
31 221297 7 142800000 147500000 Loss CNTNAP2 Gastric adenocarcinoma
32 233707 8 12700000 19100000 Gain Gastric adenocarcinoma
33 236938 8 19100000 23400000 Loss INTS10 Gastric adenocarcinoma
34 237477 8 23400000 27400000 Loss CDCA2 Gastric adenocarcinoma
35 237478 8 23400000 27400000 Loss DOCK5 Gastric adenocarcinoma
36 237479 8 23400000 27400000 Loss GNRH1 Gastric adenocarcinoma
37 237480 8 23400000 27400000 Loss KCTD9 Gastric adenocarcinoma
38 237883 8 27400000 29700000 Loss EXTL3 Gastric adenocarcinoma
39 262032 X 29400000 31500000 Gain XK Gastric adenocarcinoma

Expression for Gastric Adenocarcinoma

Search GEO for disease gene expression data for Gastric Adenocarcinoma.

Pathways for Gastric Adenocarcinoma

Pathways related to Gastric Adenocarcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 169)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.16 BRAF ERBB2 FGFR1 FGFR2 HRAS MAP2K2
2
Show member pathways
14 BRAF ERBB2 FGFR1 FGFR2 HRAS MAP2K2
3
Show member pathways
14 BRAF ERBB2 FGFR1 FGFR2 HRAS MAP2K2
4
Show member pathways
13.86 BRAF ERBB2 FGFR1 FGFR2 HRAS MAP2K2
5
Show member pathways
13.86 BRAF ERBB2 FGFR1 FGFR2 HRAS MAP2K2
6
Show member pathways
13.82 BRAF ERBB2 FGFR1 FGFR2 HRAS MAP2K2
7
Show member pathways
13.7 BRAF ERBB2 FGFR1 FGFR2 HRAS MAP2K2
8
Show member pathways
13.67 BRAF ERBB2 FGFR1 FGFR2 HRAS MAP2K2
9
Show member pathways
13.66 BRAF ERBB2 FGFR1 FGFR2 HRAS MAP2K2
10
Show member pathways
13.6 ERBB2 FGFR1 FGFR2 HRAS NRAS PIK3CA
11
Show member pathways
13.55 ERBB2 FGFR1 FGFR2 HRAS NRAS PTEN
12
Show member pathways
13.54 BRAF ERBB2 FGFR1 FGFR2 HRAS MAP2K2
13
Show member pathways
13.47 ERBB2 FGFR1 FGFR2 HRAS MAP2K2 NRAS
14
Show member pathways
13.43 ERBB2 FGFR1 FGFR2 HRAS NRAS PTEN
15
Show member pathways
13.42 BRAF ERBB2 FGFR1 FGFR2 HRAS MAP2K2
16
Show member pathways
13.26 BRAF FGFR1 FGFR2 HRAS MAP2K2 NRAS
17
Show member pathways
13.23 ERBB2 FGFR1 FGFR2 PIK3CA PTEN TP53
18
Show member pathways
13.18 FGFR1 FGFR2 HRAS MAP2K2 NRAS RAF1
19
Show member pathways
13.14 BRAF HRAS MAP2K2 NRAS RAF1 TP53
20
Show member pathways
13.14 ERBB2 FGFR1 FGFR2 HRAS MAP2K2 NRAS
21
Show member pathways
13.09 BRAF ERBB2 HRAS MAP2K2 NRAS PIK3CA
22
Show member pathways
13.09 BRAF ERBB2 HRAS MAP2K2 NRAS PIK3CA
23
Show member pathways
13.08 BRAF HRAS MAP2K2 NRAS PIK3CA RAF1
24
Show member pathways
13.06 BRAF HRAS MAP2K2 NRAS PTEN RAF1
25
Show member pathways
13.05 BRAF HRAS MAP2K2 PIK3CA PTEN RAF1
26
Show member pathways
13.02 BRAF ERBB2 FGFR1 FGFR2 HRAS MAP2K2
27
Show member pathways
12.98 BRAF HRAS MAP2K2 NRAS PIK3CA RAF1
28
Show member pathways
12.97 BRAF ERBB2 HRAS MAP2K2 NRAS PTEN
29
Show member pathways
12.96 HRAS MAP2K2 NRAS PIK3CA RAF1 TP53
30 12.96 BRAF ERBB2 FGFR1 FGFR2 HRAS MAP2K2
31
Show member pathways
12.95 BRAF HRAS MAP2K2 NRAS PTEN RAF1
32
Show member pathways
12.93 BRAF FGFR1 FGFR2 HRAS MAP2K2 NRAS
33
Show member pathways
12.93 ERBB2 FGFR1 FGFR2 HRAS NRAS PIK3CA
34
Show member pathways
12.92 BRAF HRAS MAP2K2 NRAS RAF1
35
Show member pathways
12.88 BRAF ERBB2 HRAS MAP2K2 NRAS PIK3CA
36
Show member pathways
12.85 BRAF HRAS MAP2K2 NRAS RAF1
37
Show member pathways
12.84 BRAF ERBB2 FGFR1 FGFR2 HRAS MAP2K2
38
Show member pathways
12.83 BRAF HRAS MAP2K2 NRAS RAF1 TP53
39
Show member pathways
12.82 HRAS MAP2K2 NRAS PIK3CA PTEN RAF1
40 12.82 BRAF FGFR1 FGFR2 HRAS MAP2K2 NRAS
41
Show member pathways
12.81 BRAF ERBB2 FGFR1 FGFR2 HRAS MAP2K2
42
Show member pathways
12.8 BRAF HRAS MAP2K2 NRAS RAF1
43
Show member pathways
12.78 HRAS MAP2K2 NRAS PIK3CA PTEN RAF1
44
Show member pathways
12.76 HRAS MAP2K2 NRAS PIK3CA PTEN RAF1
45 12.76 BRAF ERBB2 FGFR1 FGFR2 HRAS MAP2K2
46
Show member pathways
12.74 BRAF FGFR1 FGFR2 HRAS NRAS PIK3CA
47
Show member pathways
12.73 ERBB2 HRAS NRAS PIK3CA TP53
48 12.72 ERBB2 HRAS MAP2K2 NRAS PIK3CA PTEN
49
Show member pathways
12.69 BRAF HRAS MAP2K2 NRAS PIK3CA RAF1
50
Show member pathways
12.69 ERBB2 HRAS MAP2K2 NRAS PIK3CA PTEN

GO Terms for Gastric Adenocarcinoma

Biological processes related to Gastric Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 33)
# Name GO ID Score Top Affiliating Genes
1 phosphorylation GO:0016310 9.98 BRAF ERBB2 FGFR1 FGFR2 MAP2K2 PIK3CA
2 positive regulation of gene expression GO:0010628 9.97 BRAF ERBB2 HRAS PTEN TP53
3 angiogenesis GO:0001525 9.95 FGFR1 FGFR2 PIK3CA PTEN
4 axon guidance GO:0007411 9.91 HRAS NRAS PIK3CA SMAD4
5 protein phosphorylation GO:0006468 9.91 BRAF ERBB2 FGFR1 FGFR2 MAP2K2 PIK3CA
6 cell proliferation GO:0008283 9.88 ERBB2 HRAS PTEN RAF1 SMAD4 TP53
7 negative regulation of apoptotic process GO:0043066 9.87 BRAF ERBB2 FGFR1 FGFR2 PTEN RAF1
8 peptidyl-tyrosine phosphorylation GO:0018108 9.86 ERBB2 FGFR1 FGFR2 MAP2K2
9 positive regulation of protein kinase B signaling GO:0051897 9.84 ERBB2 FGFR1 FGFR2 PIK3CA
10 wound healing GO:0042060 9.83 ERBB2 FGFR2 RAF1
11 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.83 BRAF PIK3CA RAF1
12 positive regulation of MAPK cascade GO:0043410 9.83 ERBB2 FGFR1 FGFR2 HRAS
13 Ras protein signal transduction GO:0007265 9.82 HRAS NRAS TP53
14 positive regulation of kinase activity GO:0033674 9.81 ERBB2 FGFR1 FGFR2
15 somatic stem cell population maintenance GO:0035019 9.79 BRAF RAF1 SMAD4
16 phosphatidylinositol phosphorylation GO:0046854 9.78 ERBB2 FGFR1 FGFR2 PIK3CA
17 positive regulation of MAP kinase activity GO:0043406 9.77 ERBB2 FGFR1 HRAS
18 positive regulation of epithelial cell proliferation GO:0050679 9.77 ERBB2 FGFR2 HRAS
19 epidermal growth factor receptor signaling pathway GO:0007173 9.76 HRAS NRAS PIK3CA
20 phosphatidylinositol-3-phosphate biosynthetic process GO:0036092 9.72 FGFR1 FGFR2 PIK3CA
21 branching involved in salivary gland morphogenesis GO:0060445 9.65 FGFR1 FGFR2
22 negative regulation of signal transduction GO:0009968 9.65 BRAF ERBB2 FGFR1 FGFR2 RAF1
23 mesenchymal cell differentiation GO:0048762 9.64 FGFR1 FGFR2
24 positive regulation of phospholipase activity GO:0010518 9.62 FGFR1 FGFR2
25 lung-associated mesenchyme development GO:0060484 9.62 FGFR1 FGFR2
26 regulation of axon regeneration GO:0048679 9.58 BRAF PTEN
27 orbitofrontal cortex development GO:0021769 9.51 FGFR1 FGFR2
28 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.5 BRAF ERBB2 FGFR1 FGFR2 HRAS PTEN
29 ventricular zone neuroblast division GO:0021847 9.49 FGFR1 FGFR2
30 fibroblast growth factor receptor signaling pathway involved in orbitofrontal cortex development GO:0035607 9.46 FGFR1 FGFR2
31 ERBB2 signaling pathway GO:0038128 9.46 ERBB2 HRAS NRAS PIK3CA
32 MAPK cascade GO:0000165 9.23 BRAF ERBB2 FGFR1 FGFR2 HRAS MAP2K2
33 negative regulation of cell proliferation GO:0008285 10.03 HRAS PTEN RAF1 SMAD4 TP53

Molecular functions related to Gastric Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 protein heterodimerization activity GO:0046982 9.92 BRAF ERBB2 RAF1 SMAD4 TP53
2 kinase activity GO:0016301 9.87 BRAF ERBB2 FGFR1 FGFR2 MAP2K2 PIK3CA
3 protein kinase activity GO:0004672 9.85 BRAF ERBB2 FGFR1 FGFR2 MAP2K2 RAF1
4 protein tyrosine kinase activity GO:0004713 9.76 ERBB2 FGFR1 FGFR2 MAP2K2
5 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.69 ERBB2 FGFR1 FGFR2
6 1-phosphatidylinositol-3-kinase activity GO:0016303 9.58 FGFR1 FGFR2 PIK3CA
7 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.56 ERBB2 FGFR1 FGFR2 PIK3CA
8 MAP kinase kinase kinase activity GO:0004709 9.55 BRAF ERBB2 FGFR1 FGFR2 RAF1
9 fibroblast growth factor-activated receptor activity GO:0005007 9.43 FGFR1 FGFR2
10 mitogen-activated protein kinase kinase binding GO:0031434 9.35 BRAF ERBB2 FGFR1 FGFR2 RAF1
11 nucleotide binding GO:0000166 9.23 BRAF ERBB2 FGFR1 FGFR2 HRAS MAP2K2
12 ATP binding GO:0005524 10.08 BRAF ERBB2 FGFR1 FGFR2 MAP2K2 PIK3CA
13 identical protein binding GO:0042802 10.04 BRAF ERBB2 FGFR1 PTEN RAF1 SMAD4

Sources for Gastric Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....